The scrip opened at Rs. 2291.00 and has touched a high and low of Rs. 2307.30 and Rs. 2256.00 respectively. So far 6481 shares were traded on the counter.The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2307.30 on 12-Jul-2013 and a 52 week low of Rs. 1592.25 on 23-Jul-2012.
Last one week high and low of the scrip stood at Rs. 2307.30 and Rs. 2211.90 respectively. The current market cap of the company is Rs. 38688.89 crore.
The promoters holding in the company stood at 25.56% while Institutions and Non-Institutions held 40.69% and 16.90% respectively.
Dr Reddy's Laboratories has launched Decitabine for Injection (50mg) a therapeutic equivalent generic version of Dacogen (Decitabine for Injection) in the US market on July 11, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Decitabine for Injection.
The Dacogen brand has U.S. sales of approximately $260 Million MAT for the most recent twelve months ending in July 2013 according to IMS Health.
Dr Reddy's Decitabine for Injection 50 mg is available as a single dose vial. Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
No comments:
Post a Comment